RPCEC00000408Completed未知
Immunogenicity evaluation of the heterologous combination of two doses of SINOPHARM and one dose of SOBERANA Plus: a post-authorization study for emergency use (COVID-19) - Sinopharm-SOBERANA COVID-Cienfuegos
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Finlay Vaccine Institute
- Enrollment
- 202
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- N/a: Single Arm Study. Masking: Open. Control Group: Uncontrolled. Assignment: Single Group. Purpose: Prevention
Eligibility Criteria
- Ages
- 19 years to none (—)
- Sex
- All
Inclusion Criteria
- •1.- Subjects with 19 years or more, who were eligible for vaccination with SINOPHARM and SOBERANA Plus in the province of Cienfuegos.
- •2.- Subjects who give informed consent for blood extraction at the scheduled times.
Exclusion Criteria
- •1.- Pregnancy, puerperium or lactation.
- •2.- Subjects with a history of having suffered from COVID-19
Investigators
Similar Trials
Recruiting
Phase 4
Safety and Immunogenicity of heterologous or homologous booster after complete vaccination against COVID-19.Covid19D012141RBR-5y9y7p7Secretaria Municipal de Saúde do Rio de Janeiro
Completed
Not Applicable
Safety of Malaria vaccines in Gambian infantsPaediatricsMalariaPACTR201401000363170niversity of Oxford36
Completed
Not Applicable
Safety of Malaria vaccines in Gambian childrePaediatricsMalariaPACTR201204000362870niversity of Oxford36
Unknown
Not Applicable
Safety of Malaria vaccines in Gambian adults , children and infantsMalariaPACTR201008000221638Oxford University, Jenner Institute52
Completed
Not Applicable
Immunogenicity and Safety Outcome of Homologous and Heterologous Prime-boost of Inactivated Vaccine and Replication-defective Viral Vectors Vaccine Against SARS-CoV2 among Hemodialysis Patients: An Observational Prospective Cohort TrialTCTR20220516002Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand130